Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Korea's Genexine Forms Clinical Research Collaboration with Merck/MSD

publication date: Nov 10, 2016
Genexine of Korea entered a clinical research collaboration with Merck/MSD to test a two-drug combination as a treatment for HPV-induced cancer. The regimen will combine Genexine’s HPV therapeutic DNA vaccine and MSD’s PD-1 immunotherapy, Keytruda®. In a Phase I (solo) trial, the Genexine candidate, GX-188E, produced complete remissions of patients' CIN3 (cervical intraepithelial neoplasia) lesions in seven out of nine patients. Genexine did not disclose China plans for its drug, though the company usually out-licenses products to a domestic China pharma. Presently, neither the Genexine drug nor Keytruda is approved for China use. More details....

Stock Symbols: (KOSDAQ: 095700) (NYSE: MRK)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital